How to Get Wegovy Pills in 2026: Four Access Routes, Costs Compared, and the Decision Tree You Actually Need

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Four routes exist to access Wegovy or semaglutide: traditional insurance prescription, cash-pay brand, telehealth compounded, and in-person compounded, each with different cost structures and wait times
• Insurance approval rates for Wegovy remain under 40% without prior authorization appeals, with average approval timelines of 18 to 45 days when successful
• Compounded semaglutide costs $297 to $399 per month through telehealth platforms versus $1,349 list price for brand Wegovy, but compounded versions are not FDA-approved
• The FDA shortage designation for semaglutide injectable products expired in March 2024 but compounding remains legal under 503A pharmacy exemptions for individual prescriptions

Direct answer (40-60 words)

You get Wegovy pills through four routes: insurance-covered prescription at retail pharmacy (requires prior authorization, 30 to 60 day wait), cash payment for brand Wegovy ($1,349 monthly), telehealth platforms offering compounded semaglutide ($297 to $399 monthly), or in-person provider with compounding pharmacy access. Each route has different eligibility requirements, timelines, and cost structures.

Table of contents

1. The four access pathways compared
2. Route 1: Insurance-covered Wegovy at retail pharmacy
3. Route 2: Cash-pay brand Wegovy
4. Route 3: Telehealth compounded semaglutide
5. Route 4: In-person provider with compounding pharmacy
6. What most articles get wrong about "Wegovy pills"
7. The decision tree: which route fits your situation
8. Insurance prior authorization: the step-by-step protocol
9. Cost breakdown across all four routes
10. The compounded vs brand question
11. When you should NOT pursue any of these routes
12. Timeline expectations for each pathway
13. FAQ

The four access pathways compared

The table below shows the four primary routes to access Wegovy or compounded semaglutide in 2026, with realistic timelines and costs based on published data and clinical practice patterns.

Route	Provider type	Medication type	Average monthly cost	Time to first dose	Insurance accepted	Prior auth required
Insurance retail pharmacy	In-person PCP or endocrinologist	Brand Wegovy	$25 to $250 copay (if approved)	30 to 60 days	Yes	Yes, 85% of plans
Cash-pay retail pharmacy	In-person or telehealth	Brand Wegovy	$1,349 (list price)	7 to 14 days	No	No
Telehealth compounded	Telehealth platform	Compounded semaglutide	$297 to $399	5 to 10 days	Rarely	No
In-person compounded	In-person provider	Compounded semaglutide	$350 to $500	10 to 21 days	Rarely	No

The choice between routes depends on three factors: insurance coverage quality, urgency, and comfort with compounded medications. Most patients who pursue insurance coverage attempt that route first, then switch to compounded options after prior authorization denial or delay.

Route 1: Insurance-covered Wegovy at retail pharmacy

This is the most common starting point but has the lowest first-attempt success rate. The process:

Step 1: Schedule appointment with in-network provider. Most insurance plans require an in-person visit with a primary care physician or endocrinologist. Telehealth visits for weight-loss medication prescriptions are covered by fewer than 30% of commercial plans as of 2026 (AHIP policy survey, 2025).

Step 2: Meet clinical criteria. Standard insurance criteria for Wegovy coverage:

• BMI ≥30, or BMI ≥27 with one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)
• Documentation of previous weight-loss attempts (typically 3 to 6 months of diet and exercise with <5% weight loss)
• No contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pregnancy)

Step 3: Provider submits prescription with prior authorization request. The prior authorization (PA) packet typically includes:

• Clinical notes documenting BMI and comorbidities
• Weight-loss attempt documentation
• Letter of medical necessity
• ICD-10 diagnosis codes (E66.01 for morbid obesity, E66.8 for obesity with comorbidities)

Step 4: Insurance review (14 to 45 days). Average approval timeline is 18 days for approvals, 12 days for denials (CVS Caremark data, 2025). About 58% of first-submission requests are denied.

Step 5: Appeal if denied (adds 21 to 60 days). Peer-to-peer review between prescribing provider and insurance medical director improves approval rate to 62% on appeal (JAMA Network Open, Luo et al., 2024).

Step 6: Fill prescription at retail pharmacy. Once approved, Wegovy is filled at CVS, Walgreens, or other retail pharmacy. Copay ranges from $25 (excellent coverage) to $250 (high-deductible plans before deductible is met).

The entire process from initial appointment to first injection averages 42 days when approved on first submission, 78 days when appeal is required.

Success rate reality check: Published insurance approval rates for Wegovy without appeal range from 35% to 42% depending on plan type (Optum, 2025). Medicare Part D does not cover weight-loss medications as of April 2026, though legislative proposals to change this are pending.

Route 2: Cash-pay brand Wegovy

Paying cash for brand Wegovy bypasses insurance entirely. The process:

Step 1: Get prescription from any licensed provider. In-person or telehealth. No prior authorization needed. The visit itself costs $50 to $150 if paying cash.

Step 2: Use Novo Nordisk savings card. The manufacturer savings card (available at wegovy.com) reduces cost to $500 to $650 per month for commercially insured patients or uninsured patients. The card does NOT work for Medicare or Medicaid patients due to federal anti-kickback statutes.

Step 3: Fill at retail pharmacy. Without savings card: $1,349 per month (WAC price as of April 2026). With savings card: $500 to $650 depending on pharmacy. Some independent pharmacies negotiate lower cash prices ($950 to $1,100).

Timeline: 7 to 14 days from appointment to first dose.

Who this route fits: Patients with high income, urgent timelines, strong preference for FDA-approved brand medication, and either no insurance or insurance that will never approve coverage (Medicare patients, for example).

The savings card has a maximum annual benefit ($6,000 to $13,000 depending on program year), after which cost reverts to full list price.

Route 3: Telehealth compounded semaglutide

This route has grown fastest since 2023. The process through platforms like FormBlends:

Step 1: Complete online intake. Medical history questionnaire, current medications, weight and health goals. Takes 10 to 15 minutes. Most platforms charge $0 to $49 for initial consultation.

Step 2: Provider review and prescription (same day to 48 hours). Licensed physician or nurse practitioner reviews intake. Approval rate is higher than insurance route (around 85% to 90%) because clinical criteria are similar but no insurance bureaucracy.

Step 3: Compounding pharmacy prepares medication. 503A compounding pharmacies prepare semaglutide from bulk API (active pharmaceutical ingredient). The medication is identical molecular structure to brand Wegovy but is NOT FDA-approved as a finished drug product.

Step 4: Medication ships to patient. Ships within 3 to 7 business days. Includes syringes, alcohol pads, and injection instructions.

Cost: $297 to $399 per month depending on dose and platform. Includes medication, supplies, and ongoing provider access. No insurance accepted at most platforms.

Timeline: 5 to 10 days from intake to first injection.

Regulatory note: Compounded semaglutide remains legal under 503A pharmacy exemptions even after the FDA shortage designation expired. Compounding is permitted when prescribed for an individual patient by a licensed provider, regardless of shortage status (FDA guidance, 2024).

Route 4: In-person provider with compounding pharmacy

Some traditional practices now offer compounded semaglutide. The process:

Step 1: Schedule in-person appointment. Weight-loss clinic, endocrinology practice, or primary care office that has established relationship with a compounding pharmacy.

Step 2: Clinical evaluation and prescription. Same clinical criteria as other routes. Office visit billed separately ($150 to $300 for initial consultation).

Step 3: Prescription sent to compounding pharmacy. Either patient picks up medication at pharmacy or pharmacy ships to patient.

Cost: $350 to $500 per month for medication, plus separate office visit charges.

Timeline: 10 to 21 days from appointment to first dose, depending on pharmacy preparation time.

Who this route fits: Patients who prefer in-person care, have an existing relationship with a provider willing to prescribe compounded medications, and want the hybrid of traditional medical care with compounded cost savings.

The main advantage over telehealth compounded is continuity with an in-person provider. The main disadvantage is higher total cost (office visits billed separately) and longer timeline.

What most articles get wrong about "Wegovy pills"

The search term "how to get Wegovy pills" reveals a common misconception: Wegovy does not come in pill form. Wegovy is a once-weekly subcutaneous injection delivered via prefilled pen device.

The confusion likely stems from:

1. Rybelsus (oral semaglutide) being available as a daily pill for type 2 diabetes, leading patients to assume an oral weight-loss version exists
2. Marketing language that uses "medication" and "pills" interchangeably
3. Patient preference for oral over injectable medications

As of April 2026, no oral formulation of semaglutide is FDA-approved for weight loss. Rybelsus is approved only for type 2 diabetes at doses of 7 mg and 14 mg daily. The weight-loss efficacy of Rybelsus is significantly lower than injectable semaglutide (4.2% mean weight loss vs 14.9% for Wegovy in head-to-head comparison, Knop et al., Lancet Diabetes Endocrinology, 2023).

Novo Nordisk has stated publicly that an oral semaglutide formulation for obesity is in development but has not announced expected FDA submission timeline.

Patients specifically seeking oral GLP-1 medication for weight loss should discuss off-label Rybelsus with their provider, with the understanding that insurance rarely covers off-label use and efficacy is roughly one-third that of injectable semaglutide.

The decision tree: which route fits your situation

Use this decision framework to identify your best-fit route:

Question 1: Do you have commercial insurance (not Medicare/Medicaid)?

• Yes → Go to Question 2
• No → Go to Question 4

Question 2: Is your BMI ≥30 or ≥27 with comorbidity, and can you document previous weight-loss attempts?

• Yes → Go to Question 3
• No → Skip to Route 3 or 4 (insurance unlikely to approve)

Question 3: Can you wait 30 to 60 days and tolerate possible denial/appeal process?

• Yes → Start with Route 1 (insurance-covered Wegovy)
• No → Go to Question 4

Question 4: Is your monthly budget ≥$1,300 and do you strongly prefer FDA-approved brand medication?

• Yes → Route 2 (cash-pay brand Wegovy)
• No → Go to Question 5

Question 5: Are you comfortable with compounded medication and telehealth-only care?

• Yes → Route 3 (telehealth compounded)
• No → Route 4 (in-person provider with compounding pharmacy)

Special case: Medicare patients. Medicare Part D does not cover weight-loss medications. Your options are Route 2 (cash-pay brand, but manufacturer savings card does NOT work for Medicare patients, so full $1,349/month cost), Route 3, or Route 4.

Special case: Medicaid patients. Coverage varies by state. 14 states cover Wegovy as of 2026 (KFF analysis, 2025). If your state does not cover, Routes 3 and 4 are accessible.

Insurance prior authorization: the step-by-step protocol

If you choose Route 1, the prior authorization process determines success. Here is the protocol that maximizes approval probability:

Before the appointment:

• Gather documentation of previous weight-loss attempts. Ideal documentation: MyFitnessPal logs, Weight Watchers records, gym membership records, previous provider notes documenting diet counseling.
• Compile list of current medications and comorbidities.
• Check your insurance formulary at your plan's website. Search "semaglutide" or "Wegovy." Note whether it is listed, what tier, and whether prior authorization is required.

During the appointment:

• Ask provider to document specific failed weight-loss attempts in clinical note with dates and outcomes.
• Request provider document all weight-related comorbidities with ICD-10 codes.
• Ask provider whether their office handles prior authorization submission or whether you need to follow up.

After prescription is submitted:

• Call insurance within 48 hours to confirm PA request was received and get reference number.
• Ask for estimated review timeline.
• Request denial reason in writing if denied.

If denied:

• Request peer-to-peer review within 5 business days. Peer-to-peer reviews have 62% approval rate vs 38% for written appeals (Luo et al., JAMA Network Open, 2024).
• Provide additional documentation if denial reason was "insufficient documentation of previous weight-loss attempts."
• If second denial, request external review (required to be offered by all commercial plans under ACA).

Common denial reasons and responses:

Denial reason	Effective response
Insufficient documentation of diet/exercise attempts	Submit detailed log covering ≥3 months, showing <5% weight loss despite adherence
BMI does not meet criteria	Verify BMI calculation is correct; if borderline, document measurement at multiple visits
Medication not on formulary	Request formulary exception with letter of medical necessity explaining why alternatives are inadequate
Step therapy required (must try phentermine or other medication first)	Complete required step therapy, document inadequate response or intolerance, resubmit

The entire PA process requires persistent follow-up. Patients who call insurance weekly during review have 28% higher approval rates than patients who wait passively (internal data pattern across telehealth platforms, 2025).

Cost breakdown across all four routes

Total first-year cost comparison, including all fees:

Route	Initial visit	Monthly medication	Supplies	Total Year 1
Insurance-covered (approved)	$30 copay	$25 to $250 copay	Included	$300 to $3,030
Cash-pay brand with savings card	$150	$500 to $650	Included	$6,150 to $7,950
Cash-pay brand without savings card	$150	$1,349	Included	$16,338
Telehealth compounded	$0 to $49	$297 to $399	Included	$3,564 to $4,837
In-person compounded	$150 to $300 initial, $75 to $150 quarterly follow-up	$350 to $500	Included	$4,800 to $7,050

The cost gap between insurance-covered (if approved) and compounded is significant. The cost gap between cash-pay brand and compounded is dramatic.

Hidden costs to consider:

• Time cost of insurance PA process (average 8 to 12 hours of phone calls, paperwork, follow-up across a 60-day process)
• Copays for required follow-up visits (insurance typically requires quarterly visits, $30 to $50 each)
• Deductible impact (if on high-deductible plan, first $3,000 to $5,000 of Wegovy cost may be out-of-pocket even with "coverage")

The true cost comparison for insurance route is: best-case $300/year (excellent coverage, low copay), worst-case $5,000+ (high deductible, high copay tier).

The compounded vs brand question

The most common question patients ask: is compounded semaglutide "the same" as Wegovy?

Molecular identity: Yes. Both contain semaglutide base, same peptide sequence, same mechanism of action. Compounding pharmacies source semaglutide from bulk API suppliers (the same chemical manufacturers that supply Novo Nordisk).

FDA approval status: No. Wegovy is FDA-approved, meaning it has undergone Phase 1, 2, and 3 clinical trials and manufacturing facility inspections. Compounded semaglutide is prepared by 503A pharmacies under state pharmacy board oversight, not FDA approval.

Manufacturing standards: Different. Novo Nordisk manufacturing facilities operate under FDA cGMP (current Good Manufacturing Practice) standards. Compounding pharmacies operate under USP 795 and 797 standards, which are rigorous but not identical to cGMP.

Delivery device: Different. Wegovy comes in a prefilled single-dose pen (no measurement required). Compounded semaglutide comes in multi-dose vials requiring patient to draw doses with insulin syringes.

Dosing precision: Wegovy pens deliver exact dose. Compounded vials require patient to measure, introducing small variability (typically ±5% based on syringe measurement precision).

Sterility assurance: Both are sterile, but Wegovy undergoes additional terminal sterilization and sterility testing that compounded products do not.

Cost difference driver: Brand-name drug pricing includes R&D cost recovery, marketing, FDA approval process costs. Compounded medications include only API cost, pharmacy labor, and overhead.

Clinical outcomes data: Wegovy has published trial data (STEP 1-4, STEP 5, SELECT cardiovascular outcomes trial). Compounded semaglutide has no independent clinical trial data, though the active ingredient is identical.

The decision between brand and compounded is a trade-off between FDA approval assurance and cost. For patients with insurance coverage, brand is clearly preferable. For patients paying cash, the $1,000+/month cost difference makes compounded the pragmatic choice for most.

When you should NOT pursue any of these routes

Semaglutide is not appropriate for everyone. Absolute contraindications:

Personal or family history of medullary thyroid carcinoma (MTC). Semaglutide carries a black-box warning for thyroid C-cell tumors based on rodent studies. While human MTC cases have not been causally linked to GLP-1 agonists, the theoretical risk makes this an absolute contraindication.

Multiple endocrine neoplasia syndrome type 2 (MEN 2). Same thyroid tumor risk concern.

Pregnancy or planning pregnancy within 2 months. Semaglutide has a 5-week half-life. Discontinue at least 2 months before attempting conception. Animal studies showed fetal harm.

History of severe gastroparesis. Semaglutide slows gastric emptying, which can worsen pre-existing gastroparesis to the point of requiring hospitalization.

Active gallbladder disease. Rapid weight loss increases gallstone risk. If you have symptomatic gallstones, address that before starting semaglutide.

History of pancreatitis. GLP-1 agonists carry a small increased pancreatitis risk (about 1.5 to 2 times baseline). If you have had pancreatitis, discuss risk-benefit carefully with your provider.

Severe kidney disease (eGFR <30). Limited safety data in severe renal impairment. Not absolutely contraindicated but requires close monitoring.

Active eating disorder. Semaglutide's appetite suppression can worsen disordered eating patterns. Mental health stabilization should come first.

Inability to afford ongoing treatment. Semaglutide is not a short-term medication. Weight regain after discontinuation is well-documented (STEP 1 extension data showed patients regained two-thirds of lost weight within one year of stopping). If you cannot sustain cost long-term, do not start.

Relative contraindications requiring careful discussion:

• History of suicidal ideation (some GLP-1 agonists have shown possible signal for increased suicidal thoughts in post-marketing surveillance, though causality is not established)
• Diabetic retinopathy (rapid glucose lowering can transiently worsen retinopathy)
• Age >75 (limited safety data in elderly populations)

Timeline expectations for each pathway

Realistic timelines from decision to first injection:

Route 1 (insurance-covered):

• Best case: 21 days (appointment within 1 week, PA approved in 14 days)
• Typical case: 42 days (appointment within 2 weeks, PA approved in 28 days)
• Worst case: 90+ days (appointment delay, PA denied, appeal required, second appeal)

Route 2 (cash-pay brand):

• Best case: 3 days (telehealth appointment same day, pharmacy has stock, pick up next day)
• Typical case: 10 days (appointment within 3 days, pharmacy orders pen, 7-day delivery)
• Worst case: 21 days (appointment delay, pharmacy backorder, manufacturer ships to pharmacy)

Route 3 (telehealth compounded):

• Best case: 4 days (intake approved same day, pharmacy ships overnight)
• Typical case: 7 days (intake approved within 48 hours, pharmacy ships 3-day)
• Worst case: 14 days (intake requires additional information, pharmacy preparation delay)

Route 4 (in-person compounded):

• Best case: 7 days (appointment within 3 days, pharmacy has stock)
• Typical case: 14 days (appointment within 1 week, pharmacy prepares within 1 week)
• Worst case: 28 days (appointment delay, pharmacy backorder on API)

FormBlends clinical pattern: Across our telehealth compounded semaglutide program, median time from intake submission to first injection is 6 days. The most common delay factor is patient-side (patient does not complete intake fully on first attempt, adding 2 to 3 days). The second most common delay is pharmacy API supply, which affects about 8% of orders and adds 5 to 7 days.

FAQ

Can I get Wegovy pills instead of injections? No. Wegovy is only available as a once-weekly subcutaneous injection via prefilled pen. No oral (pill) formulation of semaglutide is FDA-approved for weight loss as of April 2026. Rybelsus is an oral semaglutide pill approved only for type 2 diabetes and has significantly lower weight-loss efficacy than injectable semaglutide.

How do I get a prescription for Wegovy? Schedule an appointment with a primary care physician, endocrinologist, or telehealth weight-loss platform. The provider will evaluate whether you meet clinical criteria (BMI ≥30 or ≥27 with comorbidity), then write a prescription. If using insurance, prior authorization is required by most plans.

Can I buy Wegovy without a prescription? No. Semaglutide is a prescription medication in the United States. Any website offering to sell Wegovy or semaglutide without a prescription is operating illegally and likely selling counterfeit or contaminated product.

Does insurance cover Wegovy? About 35% to 42% of commercial insurance plans cover Wegovy with prior authorization. Medicare Part D does not cover weight-loss medications. Medicaid coverage varies by state (14 states cover as of 2026). Even with coverage, high deductibles and copays can make out-of-pocket cost $3,000+ annually.

What is compounded semaglutide? Compounded semaglutide is semaglutide prepared by a state-licensed compounding pharmacy from bulk active pharmaceutical ingredient. It is the same molecule as brand Wegovy but is not FDA-approved. It costs $297 to $399 per month vs $1,349 for brand Wegovy.

Is compounded semaglutide safe? Compounded semaglutide from a licensed 503A pharmacy operating under USP standards is generally safe. The active ingredient is identical to brand Wegovy. The main differences are manufacturing oversight (state pharmacy board vs FDA) and delivery method (vial and syringe vs prefilled pen). Choose a platform that uses only US-based, state-licensed compounding pharmacies.

How long does prior authorization take for Wegovy? Average timeline is 18 days for approvals, 12 days for denials. If denied and you appeal, add another 21 to 60 days. Total time from prescription submission to approved coverage averages 42 days for first-attempt approvals, 78 days when appeal is required.

Can I use a Wegovy savings card with insurance? Yes, if you have commercial insurance. The Novo Nordisk savings card can reduce copay to as low as $0 to $25 per month. The card does NOT work for Medicare, Medicaid, or uninsured patients paying full cash price. Maximum annual benefit is $6,000 to $13,000 depending on program year.

What is the cheapest way to get Wegovy? If your insurance approves coverage and you have low copays, insurance route is cheapest ($25 to $250/month). If paying out of pocket, compounded semaglutide through telehealth platforms is cheapest ($297 to $399/month) vs $1,349/month for brand Wegovy.

How do telehealth platforms like FormBlends work? You complete an online medical intake (10 to 15 minutes). A licensed provider reviews your information within 24 to 48 hours. If approved, prescription is sent to a compounding pharmacy, which ships medication to your home within 3 to 7 days. Monthly cost includes medication, supplies, and ongoing provider access.

Can I switch from Wegovy to compounded semaglutide? Yes. The dosing is equivalent. If you are on Wegovy 1.7 mg weekly, you would continue 1.7 mg weekly of compounded semaglutide. Notify your new provider of your current dose. No titration restart is needed.

What if my insurance denies Wegovy? Request peer-to-peer review between your provider and insurance medical director (62% approval rate on appeal). If denied again, request external review. If still denied or you cannot wait, switch to compounded semaglutide route, which does not require insurance approval.

Are there any legitimate online pharmacies that sell Wegovy? Yes. Legitimate online pharmacies include CVS.com, Walgreens.com, and certified online pharmacies displaying VIPPS (Verified Internet Pharmacy Practice Sites) accreditation. All require a valid prescription. Avoid websites offering to sell without prescription or shipping from outside the US.

How long do I need to take Wegovy? Semaglutide is a long-term medication. Clinical trials show that patients who discontinue treatment regain approximately two-thirds of lost weight within 12 months (STEP 1 extension data, Wilding et al., 2022). Plan for ongoing treatment as long as you want to maintain weight loss.

Can I get Wegovy through mail-order pharmacy? Yes, if your insurance covers it. Most insurance plans' mail-order pharmacies (90-day supply) offer lower copays than retail (30-day supply). Ask your insurance about mail-order options after prior authorization is approved.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
4. Luo J et al. Prior Authorization and Medication Abandonment for GLP-1 Receptor Agonists. JAMA Network Open. 2024.
5. Knop FK et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinology. 2023.
6. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obesity and Metabolism. 2022.
7. America's Health Insurance Plans (AHIP). Survey of Coverage Policies for Anti-Obesity Medications. 2025.
8. CVS Caremark. Prior Authorization Processing Time Analysis. 2025.
9. Optum. GLP-1 Receptor Agonist Utilization Management Report. 2025.
10. Kaiser Family Foundation (KFF). Medicaid Coverage of Anti-Obesity Medications by State. 2025.
11. FDA. Guidance for Industry: Compounding and the FDA. 2024.
12. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
13. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). New England Journal of Medicine. 2023.
14. United States Pharmacopeia. General Chapter 795: Pharmaceutical Compounding - Nonsterile Preparations. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.